Expand VKTX Menu
VKTX MENU

VKTX Latest Press Releases

-- January 14, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 9:05 PM

-- January 8, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 12:00 PM
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PRNewswire 7:03 AM

-- January 6, 2025 --

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference PRNewswire 4:05 PM

-- January 2, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 10:20 AM

-- December 27, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 4:35 PM

-- December 3, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 7:23 PM

-- November 25, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 8:05 PM

-- November 19, 2024 --

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024 PRNewswire 4:03 PM

-- November 18, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX PRNewswire 9:52 PM

-- November 12, 2024 --

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024 PRNewswire 4:05 PM

-- November 7, 2024 --

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance Business Wire 7:00 AM

-- November 4, 2024 --

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek 2024 PRNewswire 6:30 AM

-- October 31, 2024 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 4:05 PM

-- October 28, 2024 --

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2024 PRNewswire 4:05 PM

-- October 23, 2024 --

Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- October 16, 2024 --

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024 PRNewswire 4:05 PM

-- October 9, 2024 --

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD PRNewswire 7:00 AM

-- August 28, 2024 --

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference PRNewswire 4:03 PM